WuXi AppTec raised its full-year revenue guidance after its net profit surged 62.4 per cent in the first nine months of 2026, while revenue rose 38.6 per cent on strong demand for its drug development and manufacturing services.
The Chinese pharmaceutical research services provider’s net profit reached 19.16 billion yuan (US$2.87 billion) for the nine months ended September 30, compared with 11.80 billion yuan a year earlier, a filing to the Hong Kong stock exchange showed. Its revenue rose to…
Comments